212 related articles for article (PubMed ID: 23117930)
1. Short-term pharmacological suppression of the hyperprolactinemia of infertile hCG-overproducing female mice persistently restores their fertility.
Ratner LD; Gonzalez B; Ahtiainen P; Di Giorgio NP; Poutanen M; Calandra RS; Huhtaniemi IT; Rulli SB
Endocrinology; 2012 Dec; 153(12):5980-92. PubMed ID: 23117930
[TBL] [Abstract][Full Text] [Related]
2. Genetically modified mouse models addressing gonadotropin function.
Ratner LD; Rulli SB; Huhtaniemi IT
Reprod Biol; 2014 Mar; 14(1):9-15. PubMed ID: 24607250
[TBL] [Abstract][Full Text] [Related]
3. Hyperprolactinemia induced by hCG leads to metabolic disturbances in female mice.
Ratner LD; Stevens G; Bonaventura MM; Lux-Lantos VA; Poutanen M; Calandra RS; Huhtaniemi IT; Rulli SB
J Endocrinol; 2016 Jul; 230(1):157-69. PubMed ID: 27154336
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of human chorionic gonadotropin causes multiple reproductive defects in transgenic mice.
Matzuk MM; DeMayo FJ; Hadsell LA; Kumar TR
Biol Reprod; 2003 Jul; 69(1):338-46. PubMed ID: 12672665
[TBL] [Abstract][Full Text] [Related]
5. Reproductive disturbances, pituitary lactotrope adenomas, and mammary gland tumors in transgenic female mice producing high levels of human chorionic gonadotropin.
Rulli SB; Kuorelahti A; Karaer O; Pelliniemi LJ; Poutanen M; Huhtaniemi I
Endocrinology; 2002 Oct; 143(10):4084-95. PubMed ID: 12239120
[TBL] [Abstract][Full Text] [Related]
6. Persistently expressed human chorionic gonadotropin induces premature luteinization and progressive alterations on the reproductive axis in female mice.
Marcial Lopez A; Ratner LD; Martinez CS; Di Giorgio N; Poutanen M; Huhtaniemi IT; Rulli SB
Gen Comp Endocrinol; 2023 May; 336():114247. PubMed ID: 36858273
[TBL] [Abstract][Full Text] [Related]
7. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
8. New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline.
Moro M; Inada Y; Kojima M; Miyata H; Komatsu H; Torii R
Eur J Pharmacol; 1999 Feb; 368(1):57-66. PubMed ID: 10096770
[TBL] [Abstract][Full Text] [Related]
9. A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination.
Motazedian S; Babakhani L; Fereshtehnejad SM; Mojthahedi K
Indian J Med Res; 2010 May; 131():670-4. PubMed ID: 20516539
[TBL] [Abstract][Full Text] [Related]
10. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
11. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
12. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
De Rosa M; Colao A; Di Sarno A; Ferone D; Landi ML; Zarrilli S; Paesano L; Merola B; Lombardi G
Eur J Endocrinol; 1998 Mar; 138(3):286-93. PubMed ID: 9539303
[TBL] [Abstract][Full Text] [Related]
13. Treatment versus no treatment of transient hyperprolactinemia in patients undergoing intracytoplasmic sperm injection programs.
Doldi N; Papaleo E; De Santis L; Ferrari A
Gynecol Endocrinol; 2000 Dec; 14(6):437-41. PubMed ID: 11228065
[TBL] [Abstract][Full Text] [Related]
14. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
Rains CP; Bryson HM; Fitton A
Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
[TBL] [Abstract][Full Text] [Related]
15. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Krysiak R; Okopien B
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
[TBL] [Abstract][Full Text] [Related]
16. Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience.
Arduc A; Gokay F; Isik S; Ozuguz U; Akbaba G; Tutuncu Y; Berker D; Kucukler FK; Aydin Y; Guler S
J Endocrinol Invest; 2015 Apr; 38(4):447-53. PubMed ID: 25421155
[TBL] [Abstract][Full Text] [Related]
17. The permissive role of prolactin as a regulator of luteinizing hormone action in the female mouse ovary and extragonadal tumorigenesis.
Bachelot A; Carré N; Mialon O; Matelot M; Servel N; Monget P; Ahtiainen P; Huhtaniemi I; Binart N
Am J Physiol Endocrinol Metab; 2013 Oct; 305(7):E845-52. PubMed ID: 23921141
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET.
Bahceci M; Sismanoglu A; Ulug U
Gynecol Endocrinol; 2010 Jul; 26(7):505-8. PubMed ID: 20459348
[TBL] [Abstract][Full Text] [Related]
19. Partial hypopituitarism and hyperprolactinemia: successful induction of ovulation with bromocriptine and human menopausal gonadotropins.
Dawood MY; Jarrett JC; Choe JK
Fertil Steril; 1982 Oct; 38(4):415-8. PubMed ID: 6811337
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of therapeutic outcomes of polycystic ovary syndrome patients with hyperprolactinemia].
Shi YH; Sheng Y; Chen ZJ; Yan JH; Gao Q; Liu H; Ma ZX
Zhonghua Fu Chan Ke Za Zhi; 2008 Apr; 43(4):251-3. PubMed ID: 18843962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
